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The comet assay or single cell gel electrophoresis, is the most common method used to measure 
strand breaks and a variety of other DNA lesions in human populations. To estimate the risk of 
overall mortality, mortality by cause, and cancer incidence associated to DNA damage, a cohort of 
2,403 healthy individuals (25,978 person‑years) screened in 16 laboratories using the comet assay 
between 1996 and 2016 was followed‑up. Kaplan–Meier analysis indicated a worse overall survival in 
the medium and high tertile of DNA damage (p < 0.001). The effect of DNA damage on survival was 
modelled according to Cox proportional hazard regression model. The adjusted hazard ratio (HR) was 
1.42 (1.06–1.90) for overall mortality, and 1.94 (1.04–3.59) for diseases of the circulatory system in 
subjects with the highest tertile of DNA damage. The findings of this study provide epidemiological 
evidence encouraging the implementation of the comet assay in preventive strategies for non‑
communicable diseases.
The induction of DNA damage following exposure to exogenous and endogenous agents is an important first step 
in the process of carcinogenesis. Replication of damaged DNA may lead to mutations or structural changes to 
the chromosomes, events which are critical in the development of  cancer1. The induction of genome instability 
resulting from these events is considered to be one of the critical cancer  hallmarks2, 3. In addition, most non-
communicable diseases (NCDs)—leading causes of death and disability—show characteristic phenotypes, e.g., 
accelerated aging, which are the result of accumulated DNA damage, telomere capping loss, and oxidative stress. 
DNA damage caused by oxidative reactions plays a key role in the development of  NCDs4. The most common 
method for measuring DNA damage in human populations is the comet assay, or single cell gel electrophoresis. 
In brief, agarose-embedded cells are lysed, leaving histone-depleted nuclei known as nucleoids, containing 
supercoiled DNA; breaks in the DNA relax supercoiling and the relaxed DNA loops are free to migrate under 
electrophoresis, forming a structure resembling a comet, the relative DNA content of the comet tail indicating the 
frequency of  breaks4–6. Because of its simplicity, sensitivity and speed, it has been widely adopted as a biomarker 
assay in human studies. Monitoring occupational exposure to mutagens, testing dietary supplementation with 
antioxidants, or checking levels of oxidative stress in relation to diverse diseases are among the most common 
objectives in human studies with the comet  assay5–7. Extensive literature has been published on the assay (see 
references 5–7 for a description of the protocol). The assay is generally used as a marker of exposure, but given 
the wide range of events associated with DNA damage, the comet assay is well suited to evaluate the interaction 
between lifestyle factors, environmental exposures and genetic background, and as a consequence to contribute 
to risk assessment and the surveillance of populations at risk of NCDs. Indeed, cross-sectional studies have 
demonstrated that subjects with the most prevalent NCDs have elevated levels of DNA damage, measured by 
the comet assay, in circulating  leukocytes5, 7. However, an association of DNA damage with disease does not 
mean that DNA damage is the cause of disease; it could instead be an effect. The higher level of chromosome 
damage in cancer patients, or the pre-mortem lowering of systolic blood pressure are paradigmatic examples of 
this  bias8, 9. Whether the level of DNA damage in healthy individuals is a potential marker of individual risk of 
cancer and other NCDs is a question best resolved through cohort studies, which circumvent this problem of 
reverse causality. The historical cohort design, i.e., those studies in which data on the relevant events for each 
individual (in this case the results of assays measuring genetic damage) are collected from existing records and 
can immediately be analyzed, has proven to be the best approach for the validation of genetic biomarkers as risk 
predictors. Examples of biomarkers of genomic instability that have been linked to the risk of cancer with this 
study design include the frequency of chromosomal aberrations and micronuclei in peripheral  lymphocytes10–16. 
Other biomarkers such as DNA adducts have been positively investigated using a nested case–control design 
with analysis of stored  samples17, 18, although the historical cohort approach remains the most appropriate for 
those biomarkers that are preferably evaluated on fresh tissue.
Modern epidemiological study of cancer and other chronic diseases depends increasingly on the use of large 
datasets assembled within the framework of international collaborative studies. This is also the case of the Com-
Net initiative which started in 2011 gathering a network of over 100 laboratories working with the comet  assay5, 18. 
ComNet is now subsumed in the COST Action hCOMET, which has created a database consisting of individual 
comet assay data from nearly 20,000 subjects, contributed from 105 studies performed in 44 laboratories between 
1999 and 2019. A detailed description of the database, including the list of participating laboratories and the 
baseline frequency of the assay descriptors has been recently  published19. All laboratories contributing data to 
the hCOMET database were invited to participate to a historical cohort study, assuming that they had access 
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to individual data required for a follow-up of cancer incidence and mortality, and that—after receiving ethical 
approval—they could interrogate local/national cancer registries or registries of causes of death.
The aim of the hCOMET cohort study was to provide an estimate of the association between DNA damage—as 
measured by the standard comet assay in healthy individuals—and overall mortality, mortality by cause, and 
cancer incidence for those laboratories with access to cancer registry data.
Results. To estimate the risk of overall mortality, mortality by cause, and cancer incidence associated with 
DNA damage, a cohort of 2,403 healthy individuals (25,978 person-years) screened in 16 laboratories using 
the comet assay between 1996 and 2016 was followed-up. Overall, 308 deaths were registered by the end of the 
follow-up period (median duration 10.8 years). The most common causes of death were malignant neoplasms 
(108), and diseases of the circulatory system (77). As regards cancer, gastro-intestinal (20), and genito-urinary 
(31) were the most frequent locations. One hundred and fifty-one cancer cases were recorded, mostly from labo-
ratories EU31 (31 cases) and EU33 (101 cases).
The DNA damage level measured by the comet assay is reported as DNA migration, using either length of the 
comet tail (TL), percentage of fluorescence of DNA in the comet tail (%T), the product of the TL and %T (i.e. tail 
moment, TM) or visual score (VS, based on categorization of the comets into different classes) as primary comet 
assay descriptors. A preliminary comparison of DNA damage levels between the groups of deceased, incident 
cancer cases, and subjects still alive is reported in Tables 1, 2. Mean values of the comet descriptors TM, TL, VS 
and %T were higher for the groups of deceased and cancer cases, although a statistically significant difference 
with subjects alive was only reached for %T in deceased (18.0 vs 9.0; P < 0.001) and in cancer cases (17.7 vs 12.4; 
P < 0.019), respectively. The association between mortality risk and tertile of DNA damage was further investi-
gated with the Kaplan–Meier analysis, which indicated a worse outcome in subjects in the medium or high tertile 
of DNA damage, a result which was consistent over the follow-up time, as shown by Fig. 1 (composite endpoint; 
χ22 = 19.6, P < 0.001) and Fig. 2 (%T; χ22 = 22.48, P < 0.001).
Table 1.  Selected characteristics of national cohorts. The hCOMET cohort study. na: not available; *NCD 
Patients.
Country Lab code Subjects Deaths Cancer cases Person years
Median 
follow-up 
(years) Period of test
Mean age at 
test (SD) Males (%) Exposed (%) Smokers (%)
Cuba CSA2 71 0 na 242 3.4 2015 44.4 (10.5) 87.3 0.0 57.8
Brazil CSA7 199 7 5 1,584 9.5 2008–2014 45.4 (13.7) 100.0 66.3 0.0
Italy EU15 105 2 2 1,450 15.2 2002–2007 36.4 (8.3) 29.5 28.6 44.8
Italy EU17 64 5 na 802 13.2 2002–2006 46.1 (15.9) 39.1 67.2 4.7
Italy EU18 59 0 1 578 10.1 2006–2013 29.3 (12.1) 100.0 0.0 91.5
Italy EU19 77 36 na 219 3.0 2013–2015 72.1 (8.8) 45.5 100.0* 77.9
Poland EU23 86 1 na 498 5.8 2012 44.0 (11.1) 19.8 53.5 44.2
Russia EU27 17 0 na 45 3.0 2015–2016 52.6 (13.5) 0.0 Na 23.5
Slovakia/ 
Norway EU31 738 22 31 10,403 14.3 1996–2009 43.0 (15.6) 51.4 60.0 25.5
Spain EU32 124 2 5 1,280 8.9 2003–2010 42.5 (12.3) 57.3 63.7 40.3
Spain EU33 507 217 101 3,649 7.7 2007–2013 63.1 (15.1) 62.1 100.0* 44.0
Turkey EU34 30 0 na 600 20.0 1998 28.7 (5.4) 0.0 100.0 46.7
Croatia EU4 105 0 na 1,248 12.8 2006–2008 39.6 (10.2) 59.1 46.7 38.1
Serbia EU42 32 1 na 125 4.2 2014 63.4 (11.7) 21.9 100.0* 37.5
Hungary EU50 37 0 na 433 12.0 2002–2012 38.4 (11.1) 64.9 0.0 na
France EU8 152 15 6 2,822 18.9 1997–2000 42.4 (11.2) 100.0 100.0 0.0
Total 2,403 308 151 25,978 10.8 1996–2016 47.8 (17.1) 59.8 67.4 32.2
Table 2.  Comparison of subjects diagnosed with cancer, deceased for any cause, and alive according to mean 
DNA damage level measured by the main descriptors of the comet assay. The hCOMET cohort. To ensure 
comparability, t-test was performed on standardized measures at laboratory and study level; * P < 0.001 (vs 
alive);** P = 0.017 (vs cancer free).
Vital status
Tail moment Tail length Tail intensity % Visual scoring
No Mean ± SD No Mean ± SD No Mean ± SD No Mean ± SD
Alive 233 9.1 (14.9) 316 21.8 (13.7) 956 9.0 (10.2) 1,081 73.2 (61.6)
Deceased 3 15.7 (19.3) 3 22.7 (14.1) 244 18.0 (12.8)* 66 187.2 (109.3)
Cancer- free 103 20.1 (17.1) 208 25.4 (15.4) 790 12.4 (12.0) 842 61.1 (42.5)
Cancer-cases 2 15.9 (9.1) 6 28.4 (17.2) 115 17.7 (12.5)** 36 68.7 (44.0)
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A Cox’s proportional hazard model evaluating the association between overall mortality and tertile of DNA 
damage was applied to the whole database, and results are reported in Table 3. The adjusted Hazard Ratio (HR) 
increased with the tertile of DNA damage (p for trend = 0.02) reaching statistical significance for subjects in the 
highest tertile when compared with the lowest tertile (HR = 1.42; 95% CI = 1.06–1.90; P = 0.02). Most of the other 
parameters included in the model, including age, smoking habit, and the presence of NCDs, showed significantly 
increased mortality risks, providing an intrinsic validation to study findings. Not surprisingly, the presence of 
NCD was the strongest predictor of mortality (HR = 13.2; 95% CI = 7.12–24.5; P < 0.001). The test for interaction 
and the consistency in all strata of the risk for the highest tertile of DNA damage (Table 4), confirmed that the 
presence of genotoxic exposure or a chronic disease did not modify the association between DNA damage and 
mortality rates. A complementary analysis of data shown in Table 4 using the medium tertile in the group of 
unexposed controls as the referent value for the interaction analysis confirmed (although on the basis of small 
numbers) that also in this group subjects in the highest tertile of DNA damage had the highest risk of death 
(HR = 6.07; 1.33–27.7; P = 0.02) (Supplementary Table 1). Increasing trends of HR were found also in occupation-
ally exposed subjects, and especially in subjects affected by chronic diseases. An additional analysis evaluated the 
association between DNA damage and mortality risk after removing deaths due to accidents. The association was 
a little stronger, with a HR = 1.25; 0.90–1.73 for the medium tertile and a HR = 1.52: 1.11—2.08 (p = 0.010), for 
Figure 1.  Kaplan–Meier curve for overall mortality by tertile of DNA damage (composite endpoint) measured 
with the comet assay. The hCOMET cohort.
Figure 2.  Kaplan–Meier curve for overall mortality by tertile of DNA damage (%T) measured by the Comet 
assay. The hCOMET cohort.
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the highest tertile. No effect modification due to smoking habit could be found (p = 0.959), and no increase due 
to interaction was found in the group of subjects in the highest tertile of DNA damage who smoked. To evaluate 
the consistency of the observed effects over the different laboratories, a cohort-specific analysis was performed. 
The small number of events in most cohorts allowed a proper analysis only in a few datasets. Results referring 
to groups with more than 10 deaths, i.e., EU19, EU31, EU33, and EU8 are reported in Table 5. An increased 
mortality risk associated with DNA damage was present for the highest tertile in all cohorts but EU19, although 
no single laboratory reached statistical significance. To evaluate if the overall association between DNA dam-
age and mortality was driven by a specific cohort, a sensitivity analysis was performed, sequentially removing 
a cohort from the analysis. The HR for the highest tertile of DNA damage, ranging from 1.33 to 1.51, remained 
significantly increased except when EU17, EU31 and EU33 were removed, though no major changes in the HR 
were observed.
The HR for the medium tertile ranged from 0.77 to 1.31, was never significant, and was only once below 1.0, 
when EU33 was removed. The analysis for specific causes of death showed the strongest association for the sub-
group of gastro-intestinal cancers (medium tertile; HR = 3.63; 0.71–18.50, and high tertile; HR = 7.45: 1.55–35.8, 
P = 0.012). In the group of genito-urinary cancers, the association was more evident for prostate and bladder 
cancers (high tertile; HR = 1.99: 0.76–5.20). A significant association with diseases of the circulatory system 
was found with the highest tertile of DNA damage (high tertile; HR = 1.94; 1.04–3.59, P = 0.036) (Table 6). In 
general, the small number of events limited the statistical power of these comparisons and the causes of death 
that could be studied.
To investigate if the proximity to the end of follow-up might have affected the strength of the association a 
sensitivity analysis was performed stratifying the results by distance from the final event using a cut-off of five 
Table 3.  Overall mortality risk by tertile of DNA damage measured with the comet assay (composite 
endpoint), age, sex, smoking habit, and occupational exposure/disease. The hCOMET cohort. For some 
predictors the sum of the frequencies of each category does not amount to the overall due to missing values.
Deaths (no.) Subjects (no.) Hazard ratio 95% confidence interval P value
DNA damage
Low tertile 78 829 1 -
Medium tertile 96 792 1.24 0.91–1.68 0.176
High tertile 134 782 1.42 1.06–1.90 0.02
Age at test (years) 308 2,403 1.09 1.07–1.10  < 0.001
Sex
Females 107 965 1 -
Males 201 1,438 1.17 0.89–1.53 0.253
Smoking
Non-smokers 139 1,478 1 -
Smokers 148 774 1.43 1.09–1.88 0.01
Exposure
Controls 13 781 1 -
Occupationally exposed 41 989 1.28 0.64–2.56 0.488
NCD patients 254 616 13.2 7.12–24.5  < 0.001
Table 4.  Overall mortality risk by tertile of DNA damage measured with the comet assay (composite 
endpoint). Interaction analysis by occupational exposure/disease. The hCOMET cohort. Estimates adjusted for 
age, sex, smoking habit. For some predictors the sum of the frequencies of each categories does not amount to 
the overall due to missing values.
Deaths (no.) Subjects (no.) Hazard ratio 95% confidence interval P value
Controls 13 781 1.00 - -
Occupationally exposed
Low tertile 12 349 1.10 0.47–2.55 0.828
Medium tertile 12 314 1.18 0.51–2.73 0.704
High tertile 17 326 1.52 0.70–3.34 0.291
NCD patients
Low tertile 65 208 11.2 5.75–21.7  < 0.001
Medium tertile 82 204 14.1 7.42–26.8  < 0.001
High tertile 107 204 14.5 7.72–27.3  < 0.001
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years. The HR for the highest tertile of DNA damage was consistent in both periods, i.e., HR = 1.36; 0.93–2.00, 
and HR = 1.53; 0.96–2.44, respectively (see Supplementary Table 2).
Discussion. The results of the present study provide support for the hypothesis that an increased level of 
DNA damage represents a relevant event in the pathway leading to chronic disease and eventually to death. In 
addition, the use of circulating leukocytes suggests that DNA damage can be suitably measured in this surrogate 
tissue to estimate mortality risk. The observation that the association between DNA damage and risk of death is 
not dependent on the proximity with the outcome, i.e., is not driven by the possible presence of the disease, is 
consistent with the hypothesis that measuring DNA damage in healthy subjects at any time may predict NCD 
and death. The small size of the cohort calls for longer follow-up period, and the heterogeneity of the primary 
comet assay descriptors suggests that further insight into collinearity may reduce the risk of misclassification.
Genome instability represents an enhanced accumulation of mutations, and has been recognized as a hallmark 
of several chronic diseases and  ageing20. The comet assay is considered among the most suitable methods for 
Table 5.  Mortality risk by laboratory and tertile of DNA damage measured with the comet assay (composite 
endpoint). Laboratories with at least 10 deaths were considered. The hCOMET cohort. Estimates adjusted for 
age, sex, smoking habit, and occupational exposure.
Deaths (no.) Subjects (no.) Hazard ratio 95% confidence interval P value
EU19
Low tertile 14 27 1 -
Medium tertile 11 25 0.72 0.31–1.68 0.447
High tertile 11 25 0.97 0.41–2.32 0.946
EU31
Low tertile 6 250 1 -
Medium tertile 5 245 0.89 0.27–2.99 0.855
High tertile 11 243 1.82 0.67–4.97 0.243
EU33
Low tertile 51 169 1 -
Medium tertile 71 169 1.28 0.88–1.85 0.19
High tertile 95 169 1.3 0.91–1.86 0.147
EU8
Low tertile 3 60 1 -
Medium tertile 5 46 1.01 0.22–4.58 0.997
High tertile 7 46 1.58 0.39–6.35 0.522
Table 6.  Mortality risk by selected causes of death and tertile of DNA damage measured with the comet assay 
(composite endpoint). The hCOMET cohort. Estimates adjusted for age, sex, smoking habit, and occupational 
exposure. In brackets ICD-9 (International Classification of Diseases-9) codes.
Deaths (no.) Hazard ratio 95% confidence interval P value
All neoplasms (140–239)
Low tertile 25 1 - -
Medium tertile 37 1.46 0.87–2.45 0.153
High tertile 46 1.53 0.92–2.55 0.104
Gastro-intestinal neoplasms (150–157)
Low tertile 2 1 - -
Medium tertile 6 3.63 0.71–18.5 0.121
High tertile 12 7.45 1.55–35.8 0.012
Prostate and bladder neoplasms (185,188)
Low tertile 6 1 - -
Medium tertile 10 1.68 0.60–4.69 0.32
High tertile 15 1.99 0.76–5.20 0.159
Diseases of the circulatory system (390–459)
Low tertile 18 1 - -
Medium tertile 23 1.48 0.78–2.80 0.23
High tertile 36 1.94 1.04–3.59 0.036
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monitoring DNA damage in population studies. It is a simple, fast, accurate, inexpensive method that requires 
small sample volumes and can be performed on frozen blood or buffy  coat25. This assay fulfils all criteria for 
routine use in large-scale molecular epidemiology studies and clinical disease management, especially with the 
recent development of high throughput versions; in addition, modifications of the protocol allow the detection 
of a variety of lesions and DNA repair  activity21. There have been many reports over the years of elevated DNA 
damage levels (strand breaks and/or oxidized bases) associated with a wide range of clinical conditions such 
as coronary artery disease, diabetes, kidney disease, chronic obstructive pulmonary disease, multiple sclerosis, 
and Alzheimer’s  disease4, 7, 22–25. DNA damage and DNA repair are important elements in the etiology of cancer 
and in its treatment; Vodicka and  colleagues26 reviewed the DNA damage information available for 17 types of 
cancer emphasizing the sensitivity and cost-effectiveness of the comet assay in evaluating DNA damage. Sev-
eral studies have been reported on inflammatory disorders, e.g., arthritis, inflammatory bowel disease, where 
DNA oxidation damage is often accompanied by depressed antioxidant  status27, 28. Russo et al. have tested the 
potential application of the comet assay as a prognostic tool for patients with chronic obstructive pulmonary 
disease (COPD) undergoing pulmonary  rehabilitation25. Likewise, Corredor et al. demonstrated in a cohort of 
hemodialysis patients that deceased subjects at the end of the follow-up period (approximately four years) had 
higher level of DNA strand breaks at baseline, i.e., at the entry of the study, than subjects still  alive29. Despite the 
strong evidence from cross-sectional studies linking the presence of several chronic diseases with an increased 
level of DNA damage, and the extensive literature on mechanisms, clearly showing that elevated levels of DNA 
damage are associated with several NCDs, it remains a challenge to prove that DNA damage is a cause rather 
than an effect of the disease. The most suitable epidemiologic approach to evaluate long-term effects when the 
biomarker may be affected by the disease, i.e., reverse causality bias, is the cohort study, generally with a non-
concurrent design when biomarkers are involved.
The observation reported here of an association between DNA damage and overall mortality lends support 
to a possible use of DNA damage as risk biomarker, envisioning public health implications, environmental and 
occupational preventive strategies, and even diagnostic use in clinics. The higher risks of death observed for those 
covariates known to be associated with mortality, i.e., age, smoking habit, and the presence of chronic diseases, 
gave an intrinsic validation to results on DNA damage biomarkers. The use of a composite endpoint represented 
by the tertile of any descriptors measured in the original studies (when tail intensity was not available) is fully 
justified by the common target of different descriptors, i.e., measuring the extent of DNA damage. This choice was 
further supported by 1) the presence of correlation between different descriptors of the comet assay reported in 
the literature and confirmed in the hCOMET dataset, and 2) the substantial overlapping of results between %T 
and the composite endpoint. On the other hand, the positive association between the composite endpoint and 
the risk of death and NCD may have been attenuated by the use of TL, which in many instances has been dem-
onstrated to have a lower sensitivity in identifying DNA damage by known genotoxic agents.19. The underlying 
explanation is that tail length increases with DNA break frequency only up to a certain point – corresponding 
to a quite low level of damage. This reflects the fact that the comet tail is formed by broken DNA loops extend-
ing towards the anode, and so the tail length – once established – is defined by the length of the DNA loops. 
In most laboratories using software image analysis, the TL has a rather narrow dose–response relationship for 
direct strand-breaking agents such as ionizing  radiation30. The dynamic range of the TM is mainly influenced 
by %T as the TL does not differ much. Thus, the TM typically shows a linear dose–response relationship with 
ionizing  radiation31, 32.
A major concern was the possibility that the overall association with mortality was modified by the presence 
of exposure to DNA-damaging agents, or by the presence of disease. Although this hypothesis can be properly 
checked only with ad hoc  studies11, 33, the interaction analysis reported in Table 4 and Supplementary Table 1 sug-
gests that an increasing trend in the risk of death by tertile of DNA damage was present in all groups of subjects 
evaluated, i.e., non-exposed subjects, occupationally exposed subjects, and NCD patients. As regards smoking, 
the lack of interaction with DNA damage level makes it unlikely that the higher risk of death associated to the 
tertile of DNA damage could be explained by this habit. Another potential source of confounding or of effect 
modification was the presence of several sub-cohorts. This issue was addressed with a sensitivity analysis, which 
demonstrated that no single sub-cohort could change the overall results.
The presence of selection bias is a critical issue in retrospective cohort studies. Subjects may know about their 
condition, and in some cases, subjects exposed to the disease have a higher interest in participation, especially 
if the study question was controversial. This may result in a biased assessment or in a selective loss to follow-
up associated to exposure. This is hardly the case in the present study, not only because of the limited number 
of losses, but because subjects (and investigators) were not informed of the level of DNA damage, which was 
assessed only during statistical analysis of data, minimizing the possibility that results are affected by selection 
bias.
Results on specific causes of death were meaningful only for most common causes such as cardiovascular 
diseases and malignant neoplasm. The strongest association was found for gastro-intestinal cancer, showing a 
suggestive parallelism with results from similar analyses reported for the micronucleus assay and chromosome 
 aberrations10–13.
This study has a number of strengths, and several weaknesses. The major strength is the cohort design, which 
is the least affected by bias, especially the reverse causality bias, and has been used for the validation of several 
biomarkers before. It should be noted also that despite the evidence coming from cross-sectional studies, and the 
well-known mechanistic models, no epidemiological evidence has been published so far, demonstrating that the 
extent of DNA damage in healthy subjects may predict the risk of death and NCD, including cancer. As regards 
limitations, the small size of the cohort and the heterogeneity of the comet assay descriptors are surely the most 
critical, although the standardization based on tertiles is a well-established approach to deal with laboratory 
variability. Besides epidemiological weaknesses, there is the need to substantiate the mechanistic link between 
8
Vol:.(1234567890)
Scientific Reports |        (2021) 11:16793  | https://doi.org/10.1038/s41598-021-95976-7
www.nature.com/scientificreports/
early genomic damage and such a long-term event as overall mortality. On the other hand, the presence of 
extensive evidence linking DNA damage to NCDs such as cardiovascular diseases and cancer, which in turn are 
the major causes of death, suggests a plausible pathway linking the extent of DNA damage to the risk of death. 
The inactivation of tumor suppressor genes or the amplification of oncogenes are well known consequences of 
DNA breakage, a process leading to the formation of the atherosclerotic  plaque34–36.
Another limitation is the possible effect of a decline in DNA repair capacity associated with ageing, oxidative 
stress and inflammation, which was not evaluated. It should be noted that the DNA repair activity may also be 
influenced by the same exposures that cause DNA damage, i.e., smoking, dietary factors as well as genotoxic 
agents in the environment and occupational settings. Thus, upregulation of the DNA repair activity may occur 
concurrently with a high rate of genotoxic insults due to external exposures.
The results of this analysis suggest a new role for the comet assay as a tool to measure risk biomarkers. The 
sensitivity analysis that showed that DNA damage can predict the risk of death independently from the duration 
of the follow-up (Supplementary Table 2) encourages further research on the use of the comet assay in long-term 
strategies aimed at preventing the risk of diseases as well as in pre-clinical applications.
In conclusion, the findings of this study strengthen the existing evidence that the level of DNA damage in 
circulating leukocytes of healthy individuals may be predictive of the risk of chronic diseases and mortality, 
reflecting events such as accelerated aging, telomere capping loss, oxidative stress and more generally genomic 
instability. These results disclose a number of issues relevant to both ethics and public health policies. However, 
applicability at the individual level has still to be established because of the low absolute level of risk observed 
and the large inter-individual variability of these results, not forgetting the role of individual parameters such as 
DNA repair competence. Nevertheless, from now on the use of assays measuring DNA damage to predict the risk 
of NCD diseases and mortality in population groups exposed to environmental or occupational risks or bearing 
a susceptible genetic profile should be considered for inclusion in public health strategies.
Material and methods
Study design and cohorts. The study design replicated the approach followed by similar  studies10–16. All 
44 laboratories contributing data to the hCOMET database within the framework of the hCOMET EU COST 
Action CA15132 were invited to participate to a pooled historical cohort study. The criteria for inclusion of 
laboratories in the full-scale study included 1) having had data published in peer-reviewed literature report-
ing the comet assay protocol used, and 2) providing evidence that personal identification was available for all 
subjects and the mortality follow-up was feasible through linkage with national/local cause of death registries. 
Data on cancer incidence were recorded when contact with cancer registry was available. A detailed description 
of the protocol used for the assay was collected from each laboratory submitting a database and evaluated by 
the hCOMET steering committee for compliance to standard  methodology6. In brief, subjects who underwent 
DNA damage screening with the comet assay applied to circulating leukocytes for biomonitoring purposes were 
followed from the date of the assay until the date of death, emigration, or the end of a defined follow-up period 
(December 2017–January 2019, depending on the country), whichever occurred first. The median duration 
of the follow-up was 10.8 years. Only adult subjects with valid demographic data, without a previous cancer 
diagnosis at the time of test were included. Overall, 2,403 subjects, corresponding to 25,978 person-years, were 
contributed to the hCOMET cohort by 16 laboratories from Brazil, Italy, Poland, Russia, Slovakia, Norway, 
Spain, Croatia, Serbia, Cuba, France, Turkey, and Hungary. All laboratories scored a minimum of 100 comets 
per individual sample, and all subjects were sampled only once. More detail on the characteristics of the cohort is 
reported in Table 1. In the large majority of the cohort (nearly 98%), information on cause-specific mortality was 
obtained through linkage with local/national registries or with hospital records. In the remaining 2% an active 
system of follow-up for mortality was set up via personal knowledge. Overall, 308 deaths were registered and 
coded using the ICD-IX classification system. Data on cancer incidence (151 cases) were extremely heterogene-
ous within different laboratories, with results substantially based on two laboratories, EU31 and EU33, and were 
affected by a generally poor quality of cancer diagnosis (40.1% of cases were assessed via medical records or by 
personal knowledge). The limited reliability of case-assessment, and the heterogeneous report of confounders 
by different centers prevented any further analyses of data relating to cancer incidence, which have not been 
reported among the results. All individual studies contributing data to the hCOMET cohort had already received 
approval from local ethical committees, and the informed consent for the collection and analysis of individual 
coded data was signed by all study subjects. The analysis of individual coded data was run in accordance with 
the Declaration of Helsinki and with the measures of the General Data Protection Regulation (EU) 2016/679 
(GDPR). The pooled analysis of data was approved by the ethics committee of the IRCCS San Raffaele Roma, 
Rome, Italy (12 December 2015, Prot. N. 10/15), the centre coordinating data collection and running the statisti-
cal analysis of data.
The hCOMET database
More detail about the study design and the quality procedures implemented in each study can be found in the 
original papers (Supplementary list of references) and summarized in the previous publications of the con-
sortium,5, 19, 37 which included data from 19,350 subjects, contributed by 44 laboratories. In addition, available 
information was collected concerning demographic parameters, lifestyle, occupational exposure, smoking, diet, 
genetic profile, and diagnoses of chronic diseases. To take into consideration the extensive heterogeneity of 
methods used in different laboratories, special care has been given to the hCOMET questionnaire collecting 
protocol description and technical features. Separate analyses were performed for each descriptor of the comet 
assay, namely tail intensity (%T), tail length (TL), tail moment (TM), and visual scoring (VS) to compare the 
different sensitivity of the four descriptors. To standardize for the large interlaboratory variation, mostly due to 
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exposure to genotoxic agents, cell type (isolated lymphocytes or whole blood), and sample processing (fresh/
frozen)19 , all subjects were classified within each laboratory according to tertile frequency of each descriptor 
as follows: low (1–33 percentile), medium (34–66 percentile) or high (67–100 percentile). The approach based 
on tertiles was the most efficient according to the Akaike information criteria when compared in the pooled 
database with other methods of standardization such as z scores and deviation from the  mean13, 38. To increase 
the number of events suitable for analysis, the %T sub-cohort, the descriptor with more observations, and 
generally considered the most reliable,5, 37, was enriched with data from other descriptors, creating a composite 
endpoint that represented the primary endpoint of the analysis. Whenever %T was not measured in the original 
studies, but other descriptors were available, the tertile of DNA damage was estimated using the mean value of 
tertiles from the other markers, rounded to the nearest integer. This approach was based on the assumption that 
all descriptors of the comet assay provide suitable measure DNA damage within each of the included studies.
Individual studies.
The individual studies contributing data to the cohort are listed in the Supplementary list of references. Sample 
size ranged from 17 to 738 subjects, and studies were performed between 1996 and 2016. Information on age 
and sex was available for all subjects, while smoking status at the time of testing was available for 93.0% of the 
study subjects, with 32.2% declaring to have smoked during their life. The number of cigarettes smoked was 
available only for a small proportion of subjects. The number of subjects considered exposed to genotoxic agents 
or affected by disease in the original studies represented 66.8% of the whole cohort. Nine laboratories investi-
gated various occupational exposures, four studied patients affected by chronic diseases, and three studied non 
exposed subjects. A description of all exposure groups by laboratory and by type of exposure/disease appears 
in the Supplementary Table 3.
Statistical analysis
The Kaplan–Meier product-limit method was applied to estimate the survival time after comet assay testing by 
different tertiles of DNA damage. Survival curves were compared by the log-rank  test39. The association between 
events and the tertile of DNA damage was modeled according to the Cox proportional hazard regression model, 
adjusting for age at test (years), sex (M/F), smoking habit (yes/no), and occupational exposure/disease (unex-
posed/controls; occupationally exposed, affected by disease). Diagnostic tests did not detect any substantial viola-
tion of underlying assumptions of the Cox regression. To evaluate whether the overall association between DNA 
damage and overall mortality was driven by a specific cohort, a sensitivity analysis was performed sequentially 
removing cohorts from the analysis. The potential effect modification due to the presence of an occupational 
exposure to DNA damaging agents or of a chronic disease was explored by means of the likelihood ratio  test40. 
Due to the limited number of cases in the lowest and medium tertiles of unexposed/control subjects, the pool of 
all control subjects was used as the referent value for the interaction analysis. Additional analyses were performed 
by laboratory and by specific cause of death. Finally, to provide an additional control for confounding, data were 
analysed after applying the propensity score matching, a statistical matching technique that attempts to estimate 
the effect of exposure by accounting for the covariates that predict exposure. Results of this analysis overlapped 
almost perfectly those from traditional regression analysis (data not shown), and therefore only the latter have 
been reported. To test the possibility that the likely presence of chronic diseases could have influenced the risk 
associated with the tertile of DNA damage, we stratified the entire cohort according to the median follow-up 
time, i.e. 0–5 and > 5 years, and tested a possible effect modification due to time since test. Statistical packages 
SPSS for Windows (IBM SPSS Statistics for Windows, version 26. IBM Corp., Armonk, N.Y., USA), and STATA 
statistical software (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP) 
were used for all analyses.
Data and code availability. The database supporting the current study has not been deposited in a public 
repository because of restriction of the ethical clearance (sensitive information), but are available from the cor-
responding author on request.
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